查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953438

血友病治療市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、產品、治療方法、療法、地區和競爭格局分類），2021-2031年

Haemophilia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product, By Treatment, By Therapy, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球血友病治療市場預計將從 2025 年的 120.3 億美元成長到 2031 年的 168.2 億美元，複合年成長率為 5.75%。

治療方法包括替代療法，例如重組凝血因子和血漿衍生凝血因子，以及糾正因子VIII或IX缺乏的非因子療法。市場成長的主要驅動力是全球患者識別率的提高以及向需要持續用藥的預防性護理模式的轉變。根據世界血友病聯盟（WFH）預測，到2023年，全球確診的血友病患者將達到218,804人，隨著醫療系統日益重視出血性疾病的長期管理，這將為持續的治療需求奠定堅實的基礎。

市場概覽
預測期 2027-2031
市場規模：2025年 120.3億美元
市場規模：2031年 168.2億美元
複合年成長率：2026-2031年 5.75%
成長最快的細分市場 A型血友病A
最大的市場 北美洲

然而，先進治療方案的高昂成本對市場擴張構成重大障礙。重組凝血因子和創新治療方法的高價造成了嚴重的進入門檻，尤其是在中低收入國家，這些國家的健保報銷體系往往不完善。這種經濟差距限制了發展中地區的潛在市場，並且仍然是尋求全球擴張的製造商面臨的一大障礙。

市場促進因素

新型基因療法和根治性治療方法的引入是推動全球血友病治療格局變革的主要動力，促使治療重點從慢性疾病管理轉向一次性治療方法。這項變革的標誌是高價值治療方法的核准，這些療法只需單次給藥即可長期預防出血，從而改變了支付模式和長期收入前景。支持這一價值轉變的關鍵市場趨勢是新核准的基因療法 Beqvez 的上市，根據 Fierce Pharma 2024 年 4 月發表的題為「輝瑞獲得 FDA核准的B型血友病基因療法」的報導，該療法的定價為 350 萬美元。儘管需要大量的初始投資，但這些治療方法引起了醫療系統的極大興趣，他們希望減輕與嚴重出血性疾病相關的終身經濟負擔。

同時，非因子替代療法的快速普及正在透過減輕患者的治療負擔，徹底改變標準的預防性護理模式。市場正經歷從靜脈注射凝血因子療法到皮下注射雙特異性抗體療法的重大轉變，後者可在減少給藥頻率的同時提供持續療效。強勁的財務業績也支撐了這一趨勢。根據羅氏公司於2024年2月發布的《2023年財務報告》，非因子療法Hemlibra的年銷售額預計將達到41.47億瑞士法郎，凸顯了其在預防性護理領域的領先地位。儘管非因子療法不斷擴展，但整體治療需求依然龐大。根據世界血友病聯盟於2024年10月發布的《2023年全球年度調查報告》，全球VIII因子濃縮物的消耗量估計約為94億國際單位，顯示全球治療需求規模依然龐大。

市場挑戰

先進治療方案的高昂費用嚴重阻礙了全球血友病治療市場的成長。重組凝血因子和新型基因療法的高昂價格對許多發展中國家的醫療體系造成了難以克服的財務障礙。在公共健保體系薄弱或缺乏的國家，這些救命療法對大多數患者而言仍然遙不可及。這種經濟差距嚴重限制了製藥企業的商業性拓展，迫使它們依賴飽和的高所得市場，而新興經濟體龐大的需求卻因經濟限制而無法滿足。

這種經濟差距的後果在治療產品全球分佈不均中體現得淋漓盡致。根據世界血友病聯盟的數據，2023年高高所得國家佔全球整體VIII因子使用量的61%，而低收入國家僅佔0.3%。這種顯著的不平衡表明，儘管診斷率不斷上升，低收入國家無力承擔高昂的治療費用，人為地限制了市場潛力。因此，該行業無法將不斷成長的全球患者群體轉化為實際的收入，阻礙了整體市場擴張。

市場趨勢

隨著非因子療法的興起，延長半衰期VIII因子療法的普及正在積極重塑血友病領域的競爭格局，並再次凸顯了因子替代療法的重要性。這一趨勢包括採用新一代融合蛋白，這些融合蛋白可顯著延長循環VIII因子的半衰期，使患者能夠在減少給藥頻率的同時維持持續的高因子活性。這項變更帶來的直接商業性影響體現在近期核准的、每週只需給藥一次即可維持最高保護水準的藥物的快速市場滲透。根據賽諾菲2024年10月發布的新聞稿《賽諾菲2024年第三季業績》，僅在第三季度，延長半衰期VIII因子療法Altubio的銷售額就達到了1.72億歐元，這主要得益於患者從標準因子療法和其他療法轉而使用Altubio。

隨著凝血因子替代療法的不斷發展，新型RNA干擾療法也取得了進展，其獨特的作用機制從根本上針對凝血級聯反應。與替代因子或雙特異性抗體不同，這些研究治療方法利用小干擾RNA抑制抗凝血酶的產生，有效平衡A型血友病患者的止血功能，且不受抑制劑狀態的影響。該方法旨在透過基材的途徑實現持續的止血，標誌著與傳統蛋白質替代療法的轉變。新興的臨床數據支持了此作用機制的準確性。根據賽諾菲公司2024年6月發布的關於ISTH會議報告的新聞稿，3期臨床試驗結果顯示，該RNAi療法透過將抗凝血酵素活性維持在15%至35%之間，實現了具有臨床意義的出血控制。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球血友病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（A型血友病A、B型血友病、血友病C）
    • 依產品（重組凝血因子濃縮物、血漿衍生凝血因子濃縮物、去氨加壓素、抗纖溶藥物）
    • 透過治療（按需和預防）
    • 透過治療（替代療法、即時治療（ITI）療法、基因療法）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球血友病治療市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • BioMarin Pharmaceutical, Inc.
  • CSL Behring LLC
  • Kedrion SpA
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Octapharma AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Grifols SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5057

The Global Haemophilia Treatment Market is projected to expand from USD 12.03 Billion in 2025 to USD 16.82 Billion by 2031, registering a CAGR of 5.75%. Treatment methodologies include replacement therapies, such as recombinant and plasma-derived clotting factors, as well as non-factor agents aimed at correcting deficiencies in Factor VIII or IX. Market growth is primarily fueled by improved global patient identification and a transition toward prophylactic care models that require consistent product administration. According to the World Federation of Hemophilia, the global population of identified haemophilia patients was reported as 218,804 in 2023, creating a solid foundation for sustained therapeutic demand as healthcare systems place greater emphasis on the long-term management of bleeding disorders.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.03 Billion
Market Size 2031USD 16.82 Billion
CAGR 2026-20315.75%
Fastest Growing SegmentHaemophilia A
Largest MarketNorth America

However, market expansion faces a substantial obstacle due to the prohibitive costs of advanced therapeutic options. The high pricing of recombinant factors and innovative therapies creates significant accessibility barriers, especially in low- and middle-income countries where reimbursement structures are frequently inadequate. This economic disparity limits the addressable market within developing regions and remains a critical hurdle for manufacturers seeking to extend their global footprint.

Market Driver

The introduction of novel gene therapies and curative solutions is a major driver transforming the global haemophilia treatment landscape, shifting the focus from chronic disease management to potential one-time cures. This evolution is defined by the approval of high-value treatments offering long-term bleed protection through a single administration, which subsequently alters payer models and long-term revenue outlooks. A key market development underscores this value shift; as reported by Fierce Pharma in April 2024 in the article 'Pfizer scores FDA nod for hemophilia B gene therapy', the newly approved gene therapy Beqvez launched with a list price of $3.5 million. Despite the substantial upfront investment, such therapies are attracting significant interest from healthcare systems seeking to reduce the lifetime economic burden associated with severe bleeding disorders.

Simultaneously, the rapid adoption of non-factor replacement therapies is revolutionizing standard prophylactic care by lowering the treatment burden for patients. The market is witnessing a decisive move from intravenous clotting factors to subcutaneous bispecific antibodies that provide reduced dosing frequency and consistent efficacy. This trend is supported by strong financial performance; according to Roche's 'Finance Report 2023' released in February 2024, full-year sales of the non-factor therapy Hemlibra reached CHF 4,147 million, highlighting its dominance in prophylactic settings. While non-factor agents are expanding, overall therapeutic demand remains massive; the World Federation of Hemophilia's 'Report on the Annual Global Survey 2023', published in October 2024, indicated that global consumption of Factor VIII concentrates was approximately 9.4 billion IU, emphasizing the sustained scale of worldwide therapeutic requirements.

Market Challenge

The prohibitive costs associated with advanced therapeutic options constitute a formidable barrier to the growth of the global haemophilia treatment market. The high price tags on recombinant clotting factors and novel gene therapies create a steep financial threshold that many healthcare systems in developing regions cannot overcome. In nations where public reimbursement frameworks are insufficient or nonexistent, these life-saving treatments remain largely inaccessible to the majority of the patient population. This economic disconnect severely restricts the commercial reach of pharmaceutical manufacturers, compelling them to rely heavily on saturated high-income markets while leaving substantial demand in emerging economies unaddressed due to affordability constraints.

The consequences of this economic disparity are clearly visible in the uneven global distribution of treatment products. Data from the World Federation of Hemophilia indicates that in 2023, high-income countries were responsible for 61% of total global Factor VIII usage, whereas low-income countries contributed a mere 0.3% to global consumption. This stark imbalance demonstrates that, despite rising diagnosis rates, the market's potential is artificially capped by the inability of lower-income nations to purchase premium therapeutics. Consequently, the industry struggles to convert the growing global patient pool into tangible revenue, thereby hampering overall market expansion.

Market Trends

The widespread adoption of Extended Half-Life Factor Concentrates is actively reshaping the competitive dynamics of the haemophilia sector by renewing the relevance of factor replacement therapies amidst the rise of non-factor alternatives. This trend involves the uptake of next-generation fusion proteins that significantly extend the circulating half-life of Factor VIII, enabling patients to maintain high sustained factor activity with reduced injection frequency. The immediate commercial impact of this shift is evident in the rapid market penetration of recently approved agents that offer once-weekly dosing while preserving peak protection levels. According to Sanofi's 'Press Release: Sanofi Q3 2024' from October 2024, sales of the extended half-life therapy Altuviiio reached €172 million in the third quarter alone, driven primarily by patients switching from standard factor regimens and other therapeutics.

Parallel to the evolution of factor replacement, the advancement in Novel RNA Interference Therapeutics is introducing a distinct mechanism of action that targets the coagulation cascade at a fundamental level. Unlike replacement factors or bispecific antibodies, these investigational therapies utilize small interfering RNA to suppress antithrombin production, effectively rebalancing hemostasis for patients with either Haemophilia A or B, regardless of inhibitor status. This approach aims to provide consistent bleed protection through a substrate-independent pathway, marking a departure from traditional protein replacement strategies. New clinical data supports this mechanism's precision; according to Sanofi's June 2024 press release regarding ISTH presentations, phase 3 study results demonstrated that maintaining antithrombin activity levels between 15% and 35% via this RNAi therapy resulted in clinically meaningful bleed control for patients.

Key Market Players

  • Bayer AG
  • BioMarin Pharmaceutical, Inc.
  • CSL Behring LLC
  • Kedrion S.p.A
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Octapharma AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Grifols S.A.

Report Scope

In this report, the Global Haemophilia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Haemophilia Treatment Market, By Type

  • Haemophilia A
  • Haemophilia B
  • Haemophilia C

Haemophilia Treatment Market, By Product

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrate
  • Desmopressin
  • Antifibrinolytics Agents

Haemophilia Treatment Market, By Treatment

  • On-demand and Prophylaxis

Haemophilia Treatment Market, By Therapy

  • Replacement Therapy
  • ITI therapy and Gene Therapy

Haemophilia Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Haemophilia Treatment Market.

Available Customizations:

Global Haemophilia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Haemophilia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Haemophilia A, Haemophilia B, Haemophilia C)
    • 5.2.2. By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)
    • 5.2.3. By Treatment (On-demand and Prophylaxis)
    • 5.2.4. By Therapy (Replacement Therapy, ITI therapy and Gene Therapy)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Haemophilia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Treatment
    • 6.2.4. By Therapy
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Haemophilia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Treatment
        • 6.3.1.2.4. By Therapy
    • 6.3.2. Canada Haemophilia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Treatment
        • 6.3.2.2.4. By Therapy
    • 6.3.3. Mexico Haemophilia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Treatment
        • 6.3.3.2.4. By Therapy

7. Europe Haemophilia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Treatment
    • 7.2.4. By Therapy
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Haemophilia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Treatment
        • 7.3.1.2.4. By Therapy
    • 7.3.2. France Haemophilia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Treatment
        • 7.3.2.2.4. By Therapy
    • 7.3.3. United Kingdom Haemophilia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Treatment
        • 7.3.3.2.4. By Therapy
    • 7.3.4. Italy Haemophilia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Treatment
        • 7.3.4.2.4. By Therapy
    • 7.3.5. Spain Haemophilia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Treatment
        • 7.3.5.2.4. By Therapy

8. Asia Pacific Haemophilia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Treatment
    • 8.2.4. By Therapy
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Haemophilia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Treatment
        • 8.3.1.2.4. By Therapy
    • 8.3.2. India Haemophilia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Treatment
        • 8.3.2.2.4. By Therapy
    • 8.3.3. Japan Haemophilia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Treatment
        • 8.3.3.2.4. By Therapy
    • 8.3.4. South Korea Haemophilia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Treatment
        • 8.3.4.2.4. By Therapy
    • 8.3.5. Australia Haemophilia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Treatment
        • 8.3.5.2.4. By Therapy

9. Middle East & Africa Haemophilia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Treatment
    • 9.2.4. By Therapy
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Haemophilia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Treatment
        • 9.3.1.2.4. By Therapy
    • 9.3.2. UAE Haemophilia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Treatment
        • 9.3.2.2.4. By Therapy
    • 9.3.3. South Africa Haemophilia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Treatment
        • 9.3.3.2.4. By Therapy

10. South America Haemophilia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Treatment
    • 10.2.4. By Therapy
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Haemophilia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Treatment
        • 10.3.1.2.4. By Therapy
    • 10.3.2. Colombia Haemophilia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Treatment
        • 10.3.2.2.4. By Therapy
    • 10.3.3. Argentina Haemophilia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Treatment
        • 10.3.3.2.4. By Therapy

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Haemophilia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BioMarin Pharmaceutical, Inc.
  • 15.3. CSL Behring LLC
  • 15.4. Kedrion S.p.A
  • 15.5. Novo Nordisk A/S
  • 15.6. Pfizer, Inc.
  • 15.7. Octapharma AG
  • 15.8. Sanofi SA
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Grifols S.A.

16. Strategic Recommendations

17. About Us & Disclaimer